Agenus reports 21.2-month median survival in Phase 1b BOT+BAL study for MSS metastatic colorectal cancer
AGEN•Activity, safety and next steps
Activity appeared in immunologically “cold” tumors, supporting the program’s immune-priming rationale beyond standard checkpoint-response markers.
Safety follow-up showed no new signals, supporting a lower-dose strategy aimed at reducing immune-mediated side effects.
Findings strengthen the case to test the combination earlier, including planned Phase 3 evaluation in curative-intent neoadjuvant colon cancer.
Phase 1b results and publication
Agenus disclosed a peer-reviewed publication of mature Phase 1b results; earlier three-year efficacy data were previously presented at ESMO GI 2026.
The BOT-BAL regimen showed durable survival and tumor responses in heavily pretreated MSS metastatic colorectal cancer without active liver metastases.
